SARAH LONG: Open Payments
NPI 1033112008 · ANDERSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,425 in 75 payments from 18 companies in 2025. Trend: 2023 $1,026 · 2024 $845 · 2025 $1,425
Food & beverage: $1,425
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $244 |
| ABBVIE INC. | 8 | $215 |
| Novo Nordisk Inc | 13 | $200 |
| PFIZER INC. | 12 | $186 |
| Novartis Pharmaceuticals Corporation | 4 | $91 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $88 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Dexcom, Inc. | 2 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
Products named: QULIPTA, ZEPBOUND, MOUNJARO, ELIQUIS, Kerendia, NURTEC ODT, Rybelsus, XIFAXAN.
Industry payments across SC — which companies pay providers there.
